Crossref
Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker
Experimed · 2022
DOI: 10.26650/experimed.1082020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimed, 2022. Verfasst von İsmail Alkaç und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Alkaç, İ., İşbilen, M., Küçükkaraduman, B., Güre, A., & Vural, B. (2022). Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker. Experimed. https://doi.org/10.26650/experimed.1082020
Vancouver
Alkaç İ, İşbilen M, Küçükkaraduman B, Güre A, Vural B. Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker. Experimed. 2022. doi:10.26650/experimed.1082020
BibTeX
@article{Alka2022,
author = {Alkaç, İsmail and İşbilen, Murat and Küçükkaraduman, Barış and Güre, Ali and Vural, Burçak},
title = {Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker},
journal = {Experimed},
year = {2022},
doi = {10.26650/experimed.1082020}
}
EUVIMED